Enlivex Therapeutics is trading 6.2% down at $1.98 today as shares continue to digest the impact of last week's dilutive equity offering and related SEC filing.
- The stock remains under pressure despite a recent $80 price target reiteration from H.C. Wainwright, as the market reacts to the significant dilution.
- Today's decline represents follow-through selling and continued volatility, even as the broader biotech sector trades higher.